Peter is an accomplished and visionary leader in drug discovery with over 25 years of experience in the global pharmaceutical industry. He has demonstrated high productivity in both start-up and mature environments and is currently serving as the Chief Scientific Officer at Landcent, where he accelerates the fight against diseases of poverty.
Key Achievements and Contributions:- Pioneer in Epigenetics of Cancer Drug Discovery and Development
- Advanced multiple first-in-class NMEs against unprecedented and previously unexplored targets from inception through IND submission and clinical development.
- Opened up several novel pathways and biology for drug discovery.
- Led the Discovery and Development of LBH589/Panobinostat (HDACi)
- Guided the process from scientific concept through all phases of discovery and development.
- Achieved the first-ever FDA-approved epigenetic therapy (FARYDAK™) for relapsed/refractory Multiple Myeloma.
- Co-founder of Novartis’ Third Global R&D Center (CNIBR) in Shanghai, China
- Established a highly productive drug discovery and translational research program.
- Delivered multiple novel targets and first-in-class drug candidates into the Novartis global pipeline.
- Co-founder and Former CSO of K36 Therapeutics
- Secured $100 million in funding and led the company to be named "Overall BioPharma Startup of the Year" by BioTech Breakthrough.
- Scholarly Contributions
- Contributed over 120 peer-reviewed articles, critical reviews, and book chapters to the literature on Cancer Biology, Drug Discovery, and Development.
- Inventor/co-inventor of multiple patents.
- Awards and Recognition
- Recipient of Novartis’ highest global Award for Drug Discovery (The 2008 VIVA AWARD).
LinkedIn:
https://www.linkedin.com/in/peter-atadja-ab84971/